Mohammed Abdelsaid1, Raeonda Williams2, Trevor Hardigan2, Adviye Ergul3. 1. Charlie Norwood Veterans Administration Medical Center, Augusta, Georgia; Department of Physiology, Georgia Regents University, Augusta, Georgia. Electronic address: mabdelsaid@gru.edu. 2. Department of Physiology, Georgia Regents University, Augusta, Georgia. 3. Charlie Norwood Veterans Administration Medical Center, Augusta, Georgia; Center for Pharmacy and Experimental Therapeutics, University of Georgia College of Pharmacy, Augusta, Georgia; Department of Physiology, Georgia Regents University, Augusta, Georgia.
Abstract
AIMS: We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. MATERIALS AND METHODS: 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4weeks with either vehicle chow or chow containing 166mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabetic rats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. KEY FINDING: Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. SIGNIFICANCE: ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.
AIMS: We have shown that glycemic control with metformin or endothelin-1 (ET-1) inhibition with bosentan prevents and restores diabetes-mediated cerebral pathological remodeling and neovascularization. Our recent data suggest that linagliptin, a member of the dipeptidyl peptidase-4 inhibitor class of glucose-lowering agents, prevents cerebrovascular remodeling and dysfunction independent of its blood glucose lowering effects. We hypothesized that linagliptin prevents pathological neovascularization via the modulation of the ET-1 system. MATERIALS AND METHODS: 24-week old diabetic Goto-Kakizaki and nondiabetic Wistar rats were treated for 4weeks with either vehicle chow or chow containing 166mg/kg linagliptin. At termination, FITC-dextran was injected to visualize the vasculature. Brain sections were imaged by confocal microscopy for vascular density, tortuosity, vascular volume, and surface in both the cortex and striatum. Retinal acellular capillary formation was measured. Brain microvascular endothelial cells (BMVEC) isolated from control or diabeticrats were treated with linagliptin with or without ET-1 dual receptor antagonist and tested for angiogenic properties with cell migration and tube formation assays. KEY FINDING: Linagliptin reduced all indices of cerebral neovascularization compared with control rats. In vitro, linagliptin normalized the augmented angiogenic properties of BMVECs isolated from diabetic animals and bosentan reversed this response. Cells from diabetic animals had higher ET-1 and less ETB receptors than in control cells. Linagliptin significantly decreased ET-1 levels and increased ETB receptors. SIGNIFICANCE: ET system contributes to pathological neovascularization in diabetes as evidenced by restoration of functional angiogenesis by bosentan treatment and prevention of linagliptin-mediated improvement of angiogenesis in the in vitro model.
Authors: Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-01-28 Impact factor: 3.619
Authors: Swenja Kröller-Schön; Maike Knorr; Michael Hausding; Matthias Oelze; Alexandra Schuff; Richard Schell; Stephan Sudowe; Alexander Scholz; Steffen Daub; Susanne Karbach; Sabine Kossmann; Tommaso Gori; Philip Wenzel; Eberhard Schulz; Stephan Grabbe; Thomas Klein; Thomas Münzel; Andreas Daiber Journal: Cardiovasc Res Date: 2012-07-27 Impact factor: 10.787
Authors: Neil H White; Wanjie Sun; Patricia A Cleary; William V Tamborlane; Ronald P Danis; Dean P Hainsworth; Matthew D Davis Journal: Diabetes Date: 2010-02-11 Impact factor: 9.461